SHARPE
Reported results
- Total revenue was $139 million, an increase of 39% year-over-year.
- GAAP net income was $19 million, compared with GAAP net income of $2 million for the third quarter of 2025.
- Diluted GAAP net income per share was $0.35, compared with diluted GAAP net income per share of $0.03 in the third quarter of 2025.
- Adjusted EBITDA was $30 million, compared with $15 million for the third quarter of 2025.
- Non-GAAP diluted net income per share was $0.70, compared with $0.28 in the third quarter of 2025.
Guidance
- Full year 2026 revenue is expected to be in the range of $520 million to $530 million.
- Full year 2026 Adjusted EBITDA is expected to be in the range of $90 million to $100 million.
Notes
CareDx completed the divestiture of its Lab Products business on June 30, 2026; third quarter 2026 results do not include Lab Products revenue.
Price and volatility reaction
The stock moved +22.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -25.1 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 71.52 | 2026-10-29 |
| Close after release | 87.41 | 2026-10-30 |
| Realised move | +22.2% | close to close |
| 30d ATM IV change | -25.1 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.